<sup>212</sup>Pb: Production Approaches and Targeted Therapy Applications

Over the last decade, targeted alpha therapy has demonstrated its high effectiveness in treating various oncological diseases. Lead-212, with a convenient half-life of 10.64 h, and daughter alpha-emitter short-lived <sup>212</sup>Bi (<i>T<sub>1/2</sub></i> = 1 h),...

Full description

Bibliographic Details
Published in:Pharmaceutics
Main Authors: Konstantin V. Kokov, Bayirta V. Egorova, Marina N. German, Ilya D. Klabukov, Michael E. Krasheninnikov, Antonius A. Larkin-Kondrov, Kseniya A. Makoveeva, Michael V. Ovchinnikov, Maria V. Sidorova, Dmitry Y. Chuvilin
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Subjects:
lead-212
thorium-228
radionuclide generator
α-radiation sources
targeted alpha therapy
Online Access:https://www.mdpi.com/1999-4923/14/1/189

Internet

https://www.mdpi.com/1999-4923/14/1/189

Similar Items